NorthWest Biotherapeutics Inc (NWBO)

[seekinganswers]

DCVax (specifically DCVax-L) and ATL-DC are both autologous tumor lysate-pulsed dendritic cell (DC) vaccines targeting glioblastoma (GBM), but they are distinct products developed and manufactured by separate entities, with no direct equivalence or shared production for their respective trials.
Key Differences:Developer and Ownership:DCVax-L is the proprietary product of Northwest Biotherapeutics (NWBO), a Maryland-based biotech company. It's their lead candidate in a Phase 3 trial (NCT00045968) for newly diagnosed and recurrent GBM, involving over 300 patients across multiple sites.
ATL-DC is an investigational vaccine developed by researchers at UCLA (primarily through the lab of Dr. Robert Prins and collaborators like Dr. Linda Liau), under UCLA's Specialized Programs of Research Excellence (SPORE) in brain cancer. It's used in smaller Phase 1 trials, such as one combining it with pembrolizumab (Keytruda) for recurrent, surgically accessible GBM (NCT04201873).

Manufacturing and Supply:DCVax-L is produced at NWBO's contract manufacturing organizations (e.g., Cognate BioServices and Advent Bioservices) for their commercial-scale trials.
ATL-DC is manufactured in-house or via UCLA-affiliated facilities specifically for their academic trials. NWBO does not supply ATL-DC for UCLA's studies, even though early NWBO Phase 1/2 trials for DCVax-L were conducted collaboratively at UCLA.

Clinical Context and Focus:Both vaccines work similarly: Patient monocytes are differentiated into DCs, which are then loaded with antigens from the patient's own tumor lysate to "educate" the immune system against GBM cells. They're administered intradermally alongside standard care (surgery, radiation, temozolomide).
DCVax-L has shown promising survival extensions in large trials (e.g., median overall survival of 23.1 months vs. 16.5 months with placebo in Phase 3 interim data), with a UK marketing application under review as of mid-2025.
ATL-DC is being tested in combo therapies (e.g., with PD-1 inhibitors like pembrolizumab) to enhance immune response in recurrent GBM, with early data showing good tolerability but no large-scale survival readouts yet.